Innovation Pharmaceuticals Inc (IPIX)

[farrell90]

SS you need to review the 4/16/2018 OM update which you seemed to have missed:

Highlights as outlined below

1 Median Duration of Severe Oral Mucositis (SOM) Reduced to Less Than One Day.

a. Patients in the Brilacidin-OM group appeared to trend more favorably over the course of chemoradiation treatment according to Eastern Cooperative Oncology Group (ECOG) Performance Status—a common set of criteria used in oncology trials to assess debility.

2 No Unplanned Office Visits, Emergency Department Visits, and/or Hospital Admissions Due to OM in Brilacidin-OM Arm vs. Four in Placebo Arm

a. Brilacidin outperformed placebo in both the Initial Instance Duration of SOM and the Overall Duration of SOM

b. Across cumulative radiation dose intervals, patients in the Brilacidin-OM group consistently reported less often feeling the sensation “swollen” (approximately half of that reported for the placebo group). “Burning” sensation also was reported consistently less frequently in the Brilacidin treatment group.

3 Data Align with Previously Reported 80.3% Risk Reduction in Incidence of Severe OM in Per Protocol Population Receiving Aggressive Chemotherapy Regimen Compared to Placebo

a. Other previously released results indicate Brilacidin-OM also delayed onset of SOM.


IPIX CEO summarized the results:

Hundreds of thousands of patients would benefit from a preventative OM treatment and we’re excited that Brilacidin-OM may one day provide these patients a much-needed breakthrough treatment option.”

http://www.ipharminc.com/press-release/2018/4/16/innovation-pharmaceuticals-data-from-phase-2-brilacidin-oral-mucositis-om-trial-in-head-and-neck-cancer-show-notable-reductions-in-median-duration-of-severe-om-and-in-number-of-unplanned-visit

GLTA,Farrell